Overview

Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family

Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The central hypothesis to be tested in this study is that dual blockade of EGFR and Src pathways or proteins are distinct compared to inhibition of either kinase alone in head and neck and lung cancers.
Phase:
Phase 1
Details
Lead Sponsor:
University of Pittsburgh
Treatments:
Dasatinib
Erlotinib Hydrochloride